These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 23838924)

  • 21. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.
    Grann VR; Troxel AB; Zojwalla NJ; Jacobson JS; Hershman D; Neugut AI
    Cancer; 2005 Jun; 103(11):2241-51. PubMed ID: 15844176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor characteristics and therapy of elderly patients with breast cancer.
    Grumpelt AM; Ignatov A; Tchaikovski SN; Burger E; Costa SD; Eggemann H
    J Cancer Res Clin Oncol; 2016 May; 142(5):1109-16. PubMed ID: 26809246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer.
    Kawano A; Shimizu C; Hashimoto K; Kinoshita T; Tsuda H; Fujii H; Fujiwara Y
    Breast Cancer; 2013 Apr; 20(2):145-51. PubMed ID: 22139727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
    Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
    Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms.
    Kravchenko J; Akushevich I; Seewaldt VL; Abernethy AP; Lyerly HK
    Breast Cancer Res Treat; 2011 Jul; 128(2):483-93. PubMed ID: 21225455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer biology and ethnic disparities in breast cancer mortality in new zealand: a cohort study.
    Seneviratne S; Lawrenson R; Scott N; Kim B; Shirley R; Campbell I
    PLoS One; 2015; 10(4):e0123523. PubMed ID: 25849101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
    Cefaro GA; Genovesi D; Trignani M; DI Nicola M
    Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
    Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do clinical features and survival of single hormone receptor positive breast cancers differ from double hormone receptor positive breast cancers?
    Ng CH; Pathy NB; Taib NA; Ho GF; Mun KS; Rhodes A; Looi LM; Yip CH
    Asian Pac J Cancer Prev; 2014; 15(18):7959-64. PubMed ID: 25292095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
    Liu YR; Jiang YZ; Yu KD; Shao ZM
    Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
    Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
    Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
    Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.
    Leone J; Zwenger AO; Leone BA; Vallejo CT; Leone JP
    Am J Clin Oncol; 2019 Feb; 42(2):215-220. PubMed ID: 30499840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.